Behind Novartis’ Acquisition of Myricx: The Cancer Drug Race Moves Upstream to the Battleground of “Payload Chemistry”

The next round of competition in cancer drugs may not take place only in clinical trial wards. It may first unfold between chemical payloads and intracellular enzyme pathways. Novartis has agreed to acquire the UK cancer therapy developer Myricx Bio in a deal worth up to $1.5 billion, making the startup, founded only a few years ago, the latest high-priced target in the antibody-drug conjugate boom.

According to reports from ETPharma and British media, Novartis will pay $1.1 billion upfront, with another $400 million dependent on subsequent milestones. This structure means the buyer is willing to pay a substantial amount upfront for the platform and early-stage assets, while still tying part of the value to technology advancement, development milestones, or clinical outcomes. For a biotech company still at an early stage, this is also a typical transaction arrangement in which risk and room for imagination coexist.

Myricx’s core selling point is its NMTi payload platform. Put simply, antibody-drug conjugates usually resemble toxic drugs equipped with a navigation system: the antibody is responsible for recognizing tumor cells, while the linker and payload determine when and where the drug releases its killing power. The direction Myricx is betting on is using molecules that inhibit N-myristoyltransferase as a new type of payload, with the aim of producing sufficiently strong killing effects inside cancer cells while giving existing ADC designs an option different from traditional microtubule inhibitors or DNA-damaging drugs.

The Guardian cited Fiona Marshall, president of Novartis’ biomedical research division, as saying that Myricx’s NMTi payload platform could expand the use of ADCs across multiple tumor settings. However, currently available public information is still insufficient to judge whether this platform can demonstrate a better therapeutic window in human trials. The success or failure of an ADC depends not only on payload toxicity, but also on target selection, linker stability, tumor internalization efficiency, and the ability of normal tissue to tolerate side effects.

Myricx is headquartered in London and was reportedly spun out in 2019 from research foundations related to Imperial College London and the Francis Crick Institute. That background makes the deal not only a corporate acquisition, but also a reflection of how the UK’s basic biomedical research is being incorporated by large multinational pharmaceutical companies into global oncology drug pipelines. For academic research translation, a high-value acquisition can demonstrate the commercial appeal of early-stage science; but the real medical value must still be answered by clinical data, not the transaction amount.

Background Context

In recent years, ADCs have become one of the oncology areas where large pharmaceutical companies have been most active, because they combine antibody recognition with small-molecule cytotoxicity and, in theory, can achieve a better balance between efficacy and selectivity. As popular tumor targets become increasingly crowded, the center of competition has begun moving to a deeper level: whoever can find more suitable payloads, improve release mechanisms, or allow the same platform to span more cancer types may be able to gain leadership among the next batch of drug candidates.

Therefore, the significance of Novartis’ acquisition of Myricx should not be seen merely as another high-value oncology drug deal. It is more like an early bet by a major pharmaceutical company on the technical bottlenecks of ADCs: as targets and antibody engineering become increasingly mature, what may truly create separation are the biochemical details that are harder for general readers to see, yet determine the fate of a drug.